期刊文献+

一氧化氮、白介素、肿瘤坏死因子与肝硬化患者预后的关系 被引量:2

Correlations of serum nitric oxide,interleukin-6,interleukin-10 and tumor necrosis factor levels with the prognosis of patients with liver cirrhosis
下载PDF
导出
摘要 目的:探讨血清一氧化氮(NO)、IL-6、IL-10、肿瘤坏死因子(TNF)水平与肝硬化患者预后之间的关系.方法:采用硝酸还原酶法、ELISA法、双抗体夹心酶联免疫分析法分别测定30例健康对照者和56例肝硬化患者治疗前后的血清NO,IL-6,IL-10及TNF水平.结果:肝硬化患者的NO,IL-6,TNF水平显著升高,IL-10水平明显降低.治疗后肝功能减退组的NO (129.21±27.32μmol/L vs 92.18±25.68μmol/L,P<0.05)、IL-6(198.5±23.2 mg/L vs 147.0±19.1 mg/L,P<0.05)、TNF(179.2±23.5 pg/dL vs 121.4±17.5 pg/ dL,P<0.05)水平较治疗前有显著升高,IL-10水平则明显下降(33.4±7.2 mg/L vs 51.6±18.5 mg/L,P<0.05),而治疗后肝功能恢复组NO(58.63±12.25μmol/L vs 94.36±23.45μmol/L,P<0.05)、IL-6(90.3±12.7 mg/ L vs 148.5±15.8 mg/L,P<0.05)、TNF(78.2±14.3 pg/dL vs 124.9±20.1 pg/dL,P<0.05)水平较治疗前降低(P<0.05),IL-10水平则明显升高(89.3±18.9 mg/L vs 48.8±9.5 mg/L,P<0.05).结论:NO,IL-6,IL-10,TNF与肝硬化患者预后有关. AIM: To study the roles of serum nitric oxide (NO), interleukin-6 (IL-6), interleukin-10 (IL-10) and tumor necrosis factor (TNF) in the prognosis of patients with liver cirrhosis. METHODS: Nitrate reductase assay and doubleantibody sandwich enzyme-linked immunosorbent assay were used to examine the serum levels of NO, IL-6, IL-10 and TNF in 56 patients with liver cirrhosis before and after treatment, and 30 healthy individuals served as controls. RESULTS: High levels of NO, IL-6, and TNF and low level of IL-10 were observed in patients with cirrhosis. After treatment, the serum levels of NO (129.21 ± 27.32 μmol/L vs 92.18 ± 25.68 μmol/L, P 〈 0.05), IL-6 (198.5 ± 23.2 mg/L vs 147.0 ± 19.1 mg/L, P 〈 0.05), and TNF (179.2 ± 23.5 pg/dL vs 121.4 ± 17.5 pg/dL, P 〈 0.05) were significantly elevated while the level of IL-10 (33.4 ± 7.2 mg/L vs 51.6 ± 18.5 mg/L, P 〈 0.05) was markedly decreased in patients with aggravated hepatic function as compared with those before therapy. However, the levels of NO (58.63 ± 12.25 μmol/L vs 94.36 ± 23.45 μmol/L, P 〈 0.05), IL-6 (90.3 ± 12.7 mg/L vs 148.5 ± 15.8 mg/L, P 〈 0.05) and TNF (78.2 ± 14.3 pg/dL vs 124.9 ± 20.1 pg/dL, P 〈 0.05) were decreased while the level of IL-10 (89.3 ± 18.9 mg/L vs 48.8 ± 9.5 mg/L, P 〈 0.05) was elevated in patients with improved hepatic function after treatment in comparison with those before treatment. CONCLUSION: The serum levels of NO, IL-6, IL-10 and TNF are correlated with the prognosis of patients with liver cirrhosis.
出处 《世界华人消化杂志》 CAS 北大核心 2007年第6期659-662,共4页 World Chinese Journal of Digestology
关键词 肝硬化 一氧化氮 白细胞介素 肿瘤坏死 因子 预后 Liver cirrhosis Nitric Oxide Interleukin-6 Interleukin-10 Tumor necrosis factor Prognosis
  • 相关文献

参考文献6

二级参考文献42

  • 1Guan-BinSong JianQin QingLuo Xiao-DongShen Run-BinYan Shao-XiCai.Adhesion of different cell cycle human hepatoma cells to endothelial cells and roles of integrin β_1[J].World Journal of Gastroenterology,2005,11(2):212-215. 被引量:4
  • 2病毒性肝炎防治方案(试行)[J].中华传染病杂志,1995,13(4):241-247. 被引量:1767
  • 3[1]Oka M,Iizuka N,Yamamoto K,Gondo T,Abe T,Hazama S,Akitomi Y,Koishihara Y,Ohsugi Y,Ooba Y,Ishihara T,Suzuki T.The influence of interleukin -6 on the growth of human esophageal cancer cell lines.J Interferon Cytokine Res 1996; 16:1001-1006 被引量:1
  • 4[2]Miki S,Iwano M,Miki Y,Yamamoto M,Tang B,Yokokawa K,Sonoda T,Hirano T,Kishimoto T.Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas.FEBS Lett 1989; 250:607-610 被引量:1
  • 5[3]Lee JD,Sievers TM,Skotzko M,Chandler CF,Morton DL,McBride WH,Economou JS.Interleukin-6 production by human melanoma cell lines.Lymphokine Cytokine Res 1992; 11:161-166 被引量:1
  • 6[4]Siegall CB,Schwab G,Nordan RP,FitzGerald DJ,Pastan Ⅰ.Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.Cancer Res 1990; 50:7786-7788 被引量:1
  • 7[5]Watson JM,Sensintaffar JL,Berek JS,Martinez-Maza O.Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures.Cancer Res 1990;50:6959-6965 被引量:1
  • 8[6]Bataille R,Jourdan M,Zhang XG,Klein B.Serum levels of interleukin 6,a potent myeloma cell growth factor,as a reflect of disease severity in plasma cell dyscrasias.J Clin Invest 1989;84:2008-2011 被引量:1
  • 9[7]Tsukamoto T,Kumamoto Y,Miyao N,Masumori N,Takahashi A,Yanase M.Interleukin-6 in renal cell carcinoma.J Urol1992; 148:1778-1781; discussion 1781-1782 被引量:1
  • 10[8]Seguchi T,Yokokawa K,Sugao H,Nakano E,Sonoda T,Okuyama A.Interleukin-6 activity in urine and serum in patients with bladder carcinoma.J Urol1992; 148:791-794 被引量:1

共引文献100

同被引文献29

  • 1Lubel JS,Angus PW.Modern management of portal hypertension.Intern Med J 2005; 35:45-49. 被引量:1
  • 2Sass DA,Chang P,Chopra KB.Nonalcoholic fatty liver disease:a clinical review.Dig Dis Sci 2005; 50:171-180. 被引量:1
  • 3Lefton HB,Rosa A,Cohen M.Diagnosis and epidemiology of cirrhosis.Med Clin North Am 2009;93:787-99,vii. 被引量:1
  • 4Levy GA,Adamson G,Phillips MJ,Scrocchi LA,Fung L,Biessels P,Ng NF,Ghanekar A,Rowe A,Ma MX,Levy A,Koscik C,He W,Gorczynski R,Brookes S,Woods C,McGilvray ID,Bell D.Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced antiviral activity.Hepatology 2006; 43:581-591. 被引量:1
  • 5Biessen EA,Valentijn AR,De Vrueh RL,Van De Bilt E,Sliedregt LA,Prince P,Bijsterbosch MK,Van Boom JH,Van Der Marel GA,Abrahams PJ,Van Berkel TJ.Novel hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyeth yl)adenine with improved pharmacokinetics and antiviral activity.FASEB J 2000; 14:1784-1792. 被引量:1
  • 6Bijsterbosch MK,Ying C,de Vrueh RL,de Clercq E,Biessen EA,Neyts J,van Berkel TJ.Carriermediated delivery improves the efficacy of 9-(2-ph osphonylmethoxyethyl)adenine against hepatitis B virus.Mol Pharmacol 2001; 60:521-527. 被引量:1
  • 7Di Stefano G,Fiume L,Domenicali M,Busi C,Chieco P,Kratz F,Lanza M,Mattioli A,Pariali M,Bernardi M.Doxorubicin coupled to lactosaminated albumin:Effects on rats with liver fibrosis and cirrhosis.Dig Liver Dis 2006; 38:404-408. 被引量:1
  • 8Trauner M,Boyer JL.Bile salt transporters:molecular characterization,function,and regulation.Physiol Rev 2003; 83:633-671. 被引量:1
  • 9Fiorucci S,Antonelli E,Brancaleone V,Sanpaolo L,Orlandi S,Distrutti E,Acuto G,Clerici C,Baldoni M,Del Soldato P,Morelli A.NCX-1000,a nitric oxide-releasing derivative of ursodeoxycholic acid,ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver.J Hepatol 2003;39:932-939. 被引量:1
  • 10Fiorucci S,Antonelli E,Distrutti E,Mencarelli A,Farneti S,Del Soldato P,Morelli A.Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice.Br J Pharmacol2004; 143:33-42. 被引量:1

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部